Bio-Rad Reports Third-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Bio-Rad Labs (BIO) Tops Q3 EPS by $1.20
October 29, 2020 4:20 PM EDTBio-Rad Labs (NYSE: BIO) reported Q3 EPS of $3.00, $1.20 better than the analyst estimate of $1.80. Revenue for the quarter came in at $647.3 million versus the consensus estimate of $570.58 million.
2020 Financial Outlook:
The company currently believes that full-year 2020 year-over-year currency-neutral sales... More
